UNIVERSITY OF ILLINOIS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1859-01-01

Employees: 10K

Market Cap: -

Website: http://www.illinois.edu

Clinical Trials

Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies

Completed

Conditions: Prostate Cancer

Interventions: Drug: Placebo
Drug: Dutasteride

First Posted Date: 2012-05-09

Last Posted Date: 2020-10-12

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 139

Registration Number: NCT01594502

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Efficacy of Vitamin D in Colorectal Cancer Chemoprevention

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Placebo
Drug: Vitamin D3 (cholecalciferol)

First Posted Date: 2012-04-10

Last Posted Date: 2012-04-10

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 55

Registration Number: NCT01574027

Locations: 🇺🇸
University of Illinois at Chicago Medical Center, Chicago, Illinois, United States

Young Adult Smoker's Treatment Demand

Completed

Conditions: Smoking Cessation

Interventions: Behavioral: Online advertisement

First Posted Date: 2012-04-03

Last Posted Date: 2017-03-30

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 3070

Registration Number: NCT01569529

Locations: 🇺🇸
Institute for Health Reseach and Policy, UIC, Chicago, Illinois, United States

Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension

Phase 1

Withdrawn

Conditions: Hypertension, Pulmonary

Interventions: Drug: Carbon Monoxide

First Posted Date: 2012-02-01

Last Posted Date: 2017-06-09

Lead Sponsor: University of Illinois at Chicago

Registration Number: NCT01523548

Locations: 🇺🇸
University of Illinois at Chicago Medical Center, Chicago, Illinois, United States

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

Not Applicable

Completed

Conditions: Hodgkin's Disease
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia
Myeloproliferative Disorder
Acute Leukemia
Lymphocytic Leukemia
Myelofibrosis
Malignant Lymphoma
Multiple Myeloma
Polycythemia Vera

Interventions: Drug: fludarabine/ melphalan
Drug: fludarabine/busulfan
Drug: ATG

First Posted Date: 2011-12-26

Last Posted Date: 2018-11-08

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 100

Registration Number: NCT01499147

Locations: 🇺🇸
University of Illinois at Chicago Medical Center, Chicago, Illinois, United States

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Procedure: Allogeneic Non-Myeloablative Stem Cell Transplantation
Drug: Alemtuzumab
Drug: Sirolimus

First Posted Date: 2011-12-26

Last Posted Date: 2024-07-23

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 45

Registration Number: NCT01499888

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Health Promoters and Pharmacists in Diabetes Team Management

Not Applicable

Completed

Conditions: Diabetes Mellitus

Interventions: Behavioral: Pharmacist disease/medication management
Behavioral: Pharmacist-patient encounters
Behavioral: Pharmacist medication intensification and adherence support
Behavioral: Pharmacist communication with primary care physicians
Behavioral: Pharmacist documentation in electronic medical record
Behavioral: Health promoter-patient encounters in-person or by phone
Behavioral: Health promoter medication and lifestyle support
Behavioral: Health promoter communication with pharmacists

First Posted Date: 2011-12-23

Last Posted Date: 2018-05-03

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 244

Registration Number: NCT01498159

Locations: 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States

Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue

Completed

Conditions: Benign Prostate Tissue

First Posted Date: 2011-11-17

Last Posted Date: 2020-10-05

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 80

Registration Number: NCT01473030

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

The Effects of Lycopene on High Risk Prostatic Tissue

Phase 2

Completed

Conditions: Prostatic Neoplasms
Intraepithelial Prostatic Neoplasia

Interventions: Drug: Lycopene 30mg
Drug: Placebo

First Posted Date: 2011-09-29

Last Posted Date: 2019-11-19

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 66

Registration Number: NCT01443026

Locations: 🇺🇸
Jesse Brown VA Medical Center, Chicago, Illinois, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Stem Cell Educator Therapy in Type 2 Diabetes

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Device: Stem Cell Educator

First Posted Date: 2011-08-12

Last Posted Date: 2012-02-17

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 25

Registration Number: NCT01415726

Locations: 🇨🇳
General Hospital of Jinan Military Command, Jinan, Shandong, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy